MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China

doi:10.19982/j.issn.1000-6621.20230325

Abstract

Abstract:

The global trend in the treatment of multidrug-resistant tuberculosis (MDR-TB) is to shorter treatment durations. The MDR-Chin study is China’s first cohort study to explore all-oral short-course regimens for the treatment of MDR-TB and pre-extensive drug-resistant tuberculosis (pre-XDR-TB), validating the efficacy and safety of three different treatment regimens. The results indicated that within a 12-month follow-up after the drug withdrawal, 96% of MDR-TB patients and 83.3% of pre-XDR-TB patients achieved favorable outcomes; the overall rate of favorable outcomes was 92.9%. Although grade 3 or higher adverse events (AEs) were quite common (48.1%), most were manageable and controllable, with relatively rare serious AEs (7.7%). In the study, loss-to-follow-up rate was low, the advantages of the all-oral short-course regimen were reflected and the potential for application in resource-limited settings was displayed. In this article, the author provides an overview of the MDR-Chin study, analyzesthe advantages and disadvantages, and discusses the application and future directions of clinical research for all-oral, short-course treatment regimens in China.

Key words: Tuberculosis, pulmonary, Drug resistance, multiple, Clinical protocols, Therapeutic uses

CLC Number:

Fu Liang, Deng Guofang. MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China[J]. Chinese Journal of Antituberculosis, 2024, 46(1): 18-22. doi: 10.19982/j.issn.1000-6621.20230325

References 20

[1]	World Health Organization.Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[2]	Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med, 2012, 367(10): 931-936. doi:10.1056/NEJMra1205429.
[3]	World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resis-tant tuberculosis. Geneva: World Health Organization, 2021.
[4]	Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018, 392(10150): 821-834. doi:10.1016/S0140-6736(18)31644-1.
[5]	Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet, 2014, 383(9924): 1230-1239. doi:10.1016/S0140-6736(13)62675-6. pmid: 24439237
[6]	Milstein M, Brzezinski A, Varaine F, et al. (Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2016, 20(12):18-23. doi:10.5588/ijtld.16.0039. pmid: 28240568
[7]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
[8]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020, 382(10): 893-902. doi:10.1056/NEJMoa1901814.
[9]	Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med, 2022, 387(9):810-823. doi:10.1056/NEJMoa2119430.
[10]	Fu L, Zhang X, Xiong J, et al. Selecting an appropriate allo-ral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study. Int J Infect Dis, 2023, 135: 101-108. doi:10.1016/j.ijid.2023.08.001.
[11]	Murashov MD, LaLone V, Rzeczycki PM, et al. The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation. J Invest Dermatol, 2018, 138(3): 697-703. doi:10.1016/j.jid.2017.09.031.
[12]	张文宏, 孙峰, 李杨. 世界卫生组织新短程耐多药结核病化学治疗方案:适逢其时还是太过仓促. 中华传染病杂志, 2017, 35(12):711-714. doi:10.3760/cma.j.issn.1000-6680.2017.12.002.
[13]	Paraskevas KI, de Borst GJ, Veith FJ. Why randomized controlled trials do not always reflect reality. J Vasc Surg, 2019, 70(2): 607-614.e3. doi:10.1016/j.jvs.2019.01.052.
[14]	Derksen JWG, May AM, Koopman M. The era of alternative designs to connect randomized clinical trials and real-world data. Nat Rev Clin Oncol, 2019, 16(9): 589. doi:10.1038/s41571-019-0250-0. pmid: 31296966
[15]	Elston DM. Bias in clinical studies. J Am Acad Dermatol, 2022, 86(4): 742. doi:10.1016/j.jaad.2019.06.1287.
[16]	杨智荣, 孙凤, 詹思延. 偏倚风险评估系列:(一)概述. 中华流行病学杂志, 2017, 38(7): 983-987. doi:10.3760/cma.j.issn.0254-6450.2017.07.027.
[17]	中华医学会结核病学分会,耐多药结核病短程治疗中国专家共识编写组. 耐多药结核病短程治疗中国专家共识. 中华结核和呼吸杂志, 2019, 42(1): 5-8. doi:10.3760/cma.j.issn.1001-0939.2019.01.004.
[18]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10): 1025-1073. doi:10.3969/j.issn.1000-6621.2019.10.001.
[19]	Reuter A, Furin J. Reducing harm in the treatment of multidrug-resistant tuberculosis. Lancet, 2018, 392(10150): 797-798. doi:10.1016/S0140-6736(18)31670-2. pmid: 30215367
[20]	Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med, 2020, 8(4): 383-394. doi:10.1016/S2213-2600(20)30047-3. pmid: 32192585